NCT04400318dupilumabasthmaVESTIGEConclusionstype 2
… in patients with asthma.Methods In the phase 4 VESTIGE trial ( NCT04400318), adults (aged 21–70 years) with type 2 (eosinophils ≥300 cells…
1articles mentioning funders
1funder mentions
1distinct funders extracted
0%of mentions human-reviewed
Active filtersEntity: NCT04400318 ×
NCT04400318
This funder is selected. Its supporting articles are shown below.